Optimising the design of phase II oncology trials: the importance of randomisation.
暂无分享,去创建一个
[1] D J Schaid,et al. A design for phase II testing of anticancer agents within a phase III clinical trial. , 1988, Controlled clinical trials.
[2] P. Thall,et al. Incorporating historical control data in planning phase II clinical trials. , 1990, Statistics in medicine.
[3] T M Therneau,et al. Designs for group sequential phase II clinical trials. , 1987, Biometrics.
[4] P F Thall,et al. New designs for the selection of treatments to be tested in randomized clinical trials. , 1994, Statistics in medicine.
[5] D J Sargent,et al. A flexible design for multiple armed screening trials , 2001, Statistics in medicine.
[6] F. De Ridder,et al. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. , 2005, Basic & clinical pharmacology & toxicology.
[7] P Y Liu,et al. False positive rates of randomized phase II designs. , 1999, Controlled clinical trials.
[8] P F Thall,et al. Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.
[9] F. Holmes. Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342 , 2005 .
[10] Boris Freidlin,et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Donna Niedzwiecki,et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Bryant,et al. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.
[13] Peter F Thall,et al. Seamlessly Expanding a Randomized Phase II Trial to Phase III , 2002, Biometrics.
[14] E. Eisenhauer,et al. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[16] D. Sargent,et al. A three-outcome design for phase II clinical trials. , 2001, Controlled Clinical Trials.
[17] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[18] E. Gehan,et al. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.
[19] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[20] S. Liou,et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Sargent,et al. Assessing the measure of a new drug: is survival the only thing that matters? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Thomas R Fleming,et al. Some design issues in trials of microbicides for the prevention of HIV infection. , 2004, The Journal of infectious diseases.